Analystreport

Celldex Therapeutics, Inc. (NASDAQ: CLDX) was downgraded by analysts at HC Wainwright to a "buy" rating. They now have a $2.50 price target on the stock.

Celldex Therapeutics, Inc.  (CLDX) 
Last celldex therapeutics, inc. earnings: 11/12 08:01 am Check Earnings Report
US:NASDAQ Investor Relations: ir.celldex.com